IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

About three months ago, IGM Bio­sciences an­nounced plans to stay afloat by fo­cus­ing its re­sources on a clin­i­cal-stage au­toim­mune as­set.

Now the com­pa­ny is shelv­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER